Abstract 2062P
Background
PsyD is frequent in cancer pts and it negatively affects their treatment and quality of life. However, psychological screening is not extensively performed and few data about its impact are available. The aim of our study is to evaluate baseline PsyD in PC pts treated at our Institution and its correlation with clinicopathological features.
Methods
In the last year, we baseline evaluated PsyD of PC pts starting chemotherapy at our Institution, using the Distress Thermometer (DT) and Problem List (PL). The DT score was divided into three levels: no/minimal (0-3), moderate (4-6) and high (7-10) distress. PL was grouped into 6 categories (practical, physical, cognitive, spiritual/religious, emotional and family problems). Clinicopathological characteristics were collected and correlated with PsyD.
Results
A total of 86 PC pts were tested for baseline PsyD. The median age was 65 years, 63% were female, ECOG PS was > 1 in 56% of pts and 72% of pts had one or more comorbidities. The majority of pts (67%) received chemotherapy for metastatic disease. Regarding psychological screening, 31%, 29% and 40% of pts had no/minimal, moderate and high DT score, respectively. According to PL we observed: practical problems in 17% of patients, physical in 9%, cognitive in 42%, spiritual/religious in 9%, emotional in 16%, and family problems in 13% of patients. Regarding psycho-oncological care, 93% of pts received initial counseling, 63% intervention and follow-up. No significant association between DT score and PL groups with clinicopathological characteristics was observed.
Conclusions
Our mono-institutional analysis showed that the majority of PC pts receiving chemotherapy at our Institution presented a PsyD scored as moderate (29%) or high (40%) by DT at baseline. According to PL, the main problem concerned the cognitive sphere, specifically problems related to concentration and/or memory and self-perception. Additional analyses, including the impact of PsyD on treatment compliance, tolerability and prognosis are going.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Fondazione Policlinico Universitario Agostino Gemelli-IRCCS.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06